entity

chaperones

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about chaperones: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2Connections
2Hypotheses
2Analyses
2Outgoing
0Incoming
10Experiments
2Debates

No AI portrait yet

Outgoing (2)

TargetRelationTypeStr
misfolded proteinsselectively_targetsprocess0.70
oxidative_stress_responseparticipates_inpathway0.56

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
APOE4 Allosteric Rescue via Small Molecule Chaperones 0.765 neurodegeneration APOE4 structural biology and therapeutic
Autophagic Flux Enhancement Synergizes With Chaperones to Cl 0.649 protein-folding Can chaperone enhancement approaches ove

Mentioning Analyses (2)

Scientific analyses that reference this entity

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

drug discovery | 2026-04-09 | 7 hypotheses Top: 0.455

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

molecular biology | 2026-04-08 | 8 hypotheses Top: 0.380

Experiments (10)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] Rusmini P, Cortese K, Crippa V, Cristofa Autophagy 2019 2
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The cell biology of APOE in the brain. [PMID:37805344] Windham IA, Cohen S Trends Cell Biol 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] Yamazaki Y, Zhao N, Caulfield TR, Liu CC Nat Rev Neurol 2019 1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] Sang Y, Cao Y, Li S, Quan Y, Wang S et a Biomaterials 2026 0
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] Lin Z, Xiong J, Zhang F, Zhang H, Zhu M Mol Ther 2026 0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] Samudra N, Vemuri M, Weitlauf J Curr Opin Obstet Gynecol 2026 0
DPP4-regulated endothelial cell ferroptosis modulates atherosclerosis progressio [PMID:41565199] Zheng L, Liang K, Peng Y, Jin M, Chen X J Mol Cell Cardiol 2026 0
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disor [PMID:40145985] Lozupone M, Leccisotti I, Mollica A, Ber Neural regeneration research 2026 0
Cognitive Decline and Neurodegenerative Markers in Psoriasis: The Role of APOE4 [PMID:41912201] Sabry HH, Kadhum BQ, Abdulmohsin GN, El- Dermatology practical & concep 2026 0
Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzhe [PMID:41890452] Arriaga P, Vianna K, Montez C, Panariell Cureus 2026 0
Correlational Validity and Biomarker Associations of the Korean Computerized Cog [PMID:41911088] Kim D, Lee WJ, Jeon DH, Lee H, Kang M, P Dementia and geriatric cogniti 2026 0

Debates (2)

Multi-agent debates referencing this entity

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

closed · Rounds: 4 · Score: 0.86 · 2026-04-10

The debate identified fundamental druggability challenges for these targets due

closed · Rounds: 4 · Score: 0.95 · 2026-04-09

Related Research

Hypotheses and analyses mentioning chaperones in their description or question text

No additional research found